Related references
Note: Only part of the references are listed.Pre-clinical models for evaluating glioma targeted immunotherapies
Stephen C. Frederico et al.
FRONTIERS IN IMMUNOLOGY (2023)
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
John F. Roller et al.
CANCERS (2022)
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?
Marijo Bilusic
EXPERT REVIEW OF ANTICANCER THERAPY (2022)
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Michael Lim et al.
NEURO-ONCOLOGY (2022)
The Role of Myeloid Cells in GBM Immunosuppression
Ya-Jui Lin et al.
FRONTIERS IN IMMUNOLOGY (2022)
Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors
Ryo Kurokawa et al.
RADIOGRAPHICS (2022)
Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
M. Chalabi et al.
ANNALS OF ONCOLOGY (2022)
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
N. D. Gross et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Exploring the origin of the cancer stem cell niche and its role in anti-angiogenic treatment for glioblastoma
Funto A. Akindona et al.
FRONTIERS IN ONCOLOGY (2022)
DEVELOPING AN ADOPTIVE CELL TRANSFER IMMUNOTHERAPY FOR PEDIATRIC HIGH-GRADE GLIOMAS
Stephen Frederico et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2021)
CTIM-32. IMMUNE CHECKPOINT INHIBITOR NIVOLUMAB IN PEOPLE WITH RECURRENT SELECT RARE CNS CANCERS: RESULTS OF INTERIM ANALYSIS IN A HEAVILY PRETREATED COHORT
Marta Penas-Prado et al.
NEURO-ONCOLOGY (2021)
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Tina Cascone et al.
NATURE MEDICINE (2021)
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
Alexander H. Lee et al.
NATURE COMMUNICATIONS (2021)
Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer
Ke Xu et al.
JOURNAL OF THORACIC DISEASE (2021)
The immune suppressive microenvironment affects efficacy of radio-immunotherapy in brain metastasis
Katja Niesel et al.
EMBO MOLECULAR MEDICINE (2021)
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Angeliki Datsi et al.
FRONTIERS IN IMMUNOLOGY (2021)
PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
J. Lee et al.
Journal of Thoracic Oncology (2021)
Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects
Xin Wang et al.
CELL DEATH & DISEASE (2021)
Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?
Nuttavut Sumransub et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
Stephen C. Frederico et al.
FRONTIERS IN ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Elizabeth Ahern et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies
Nivedita M. M. Ratnam et al.
FRONTIERS IN ONCOLOGY (2021)
Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma
Yun Song et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Tumor microenvironment differences between primary tumor and brain metastases
Bernardo Cacho-Diaz et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Neoadjuvant checkpoint blockade for cancer immunotherapy
Suzanne L. Topalian et al.
SCIENCE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review
Cyrillo G. Brahm et al.
CANCERS (2020)
Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives
Mohammed Abdul-Latif et al.
CANCER TREATMENT REVIEWS (2020)
Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
Jing Zhao et al.
CHINESE MEDICAL JOURNAL (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Mariano Provencio et al.
LANCET ONCOLOGY (2020)
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
Joshua R. D. Pearson et al.
FRONTIERS IN IMMUNOLOGY (2020)
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Joshua E. Reuss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Pembrolizumab in MSI-H-dMMR Advanced Colorectal Cancer - A New Standard of Care
Axel Grothey
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2020)
The landscape of the mesenchymal signature in brain tumours
Jinan Behnan et al.
BRAIN (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
Florian Eichhorn et al.
BMC CANCER (2019)
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
Jake S. O'Donnell et al.
CLINICAL CANCER RESEARCH (2019)
Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment
Anne Dirkse et al.
NATURE COMMUNICATIONS (2019)
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Heidi Harjunpaa et al.
FRONTIERS IN IMMUNOLOGY (2019)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2019)
Vaccination in the immunotherapy of glioblastoma
Ziren Kong et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond
Jeffrey E. Gershenwald et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Daniela S. Thommen et al.
NATURE MEDICINE (2018)
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
Amber J. Giles et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Pakawat Chongsathidkiet et al.
NATURE MEDICINE (2018)
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (vol 24, pg 1649, 2018)
Rodabe N. Amaria et al.
NATURE MEDICINE (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Molecular Insights into Melanoma Brain Metastases
Dana Westphal et al.
CANCER (2017)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
Angela DeMichele et al.
CLINICAL CANCER RESEARCH (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Evidence of Glioblastoma Heterogeneity
Akio Soeda et al.
SCIENTIFIC REPORTS (2015)
Molecular heterogeneity in glioblastoma: potential clinical implications
Nicole Renee Parker et al.
FRONTIERS IN ONCOLOGY (2015)
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies
Alfredo Berruti et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Current Vaccine Trials in Glioblastoma: A Review
LindaW. Xu et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Myeloid-Derived Suppressor Cells and anti-tumor T cells: a complex relationship
Ngozi R. Monu et al.
IMMUNOLOGICAL INVESTIGATIONS (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Surgery induced immunosuppression
Brian V. Hogan et al.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND (2011)
Temozolomide (Temodar)
J. R. Wesolowski et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oligodendroglioma
Martin J. Van den Bent et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Diffuse glioma growth: a guerilla war
An Claes et al.
ACTA NEUROPATHOLOGICA (2007)
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
H Ohgaki et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
Factors influencing survival in high-grade gliomas
JC Buckner
SEMINARS IN ONCOLOGY (2003)
Tight junctions of the blood-brain barrier
U Kniesel et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2000)
Share Paper
